Clinical data | |
---|---|
Trade names | Brevital Sodium |
Other names | Methohexitone |
AHFS/Drugs.com | Consumer Drug Information |
License data |
|
Routes of administration | Intravenous, rectal |
Drug class | Barbiturate |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | I.V. ~100% Rectal ~17% |
Metabolism | Liver |
Elimination half-life | 5.6 ± 2.7 minutes |
Excretion | excreted in feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.272 |
Chemical and physical data | |
Formula | C14H18N2O3 |
Molar mass | 262.309 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Methohexital or methohexitone (marketed under the brand names Brevital and Brietal) is a drug which is a barbiturate derivative. It is classified as short-acting, and has a rapid onset of action.[2] It is similar in its effects to sodium thiopental, a drug with which it competed in the market for anesthetics.
Brevital Sodium FDA label
was invoked but never defined (see the help page).